» Articles » PMID: 1678081

Relation of Cellular Drug Resistance to Long-term Clinical Outcome in Childhood Acute Lymphoblastic Leukaemia

Overview
Journal Lancet
Publisher Elsevier
Specialty General Medicine
Date 1991 Aug 17
PMID 1678081
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

The clinical relevance of cellular drug resistance in children with acute lymphoblastic leukaemia (ALL) is unknown. The relation between in-vitro sensitivity to chemotherapeutic drugs at initial diagnosis and long-term clinical outcome was investigated in 44 children with ALL. The short-term MTT assay was used to assess sensitivity to prednisolone, vincristine, colaspase (asparaginase), daunorubicin, and thioguanine (instead of mercaptopurine which is unstable in vitro). For vincristine and colaspase there was no difference in outcome (probability of continuous complete remission) between sensitive and resistant patients. However, the probability of continuous complete remission was significantly lower in patients with resistant cells than in those with sensitive cells for thioguanine (p less than 0.01), daunorubicin (p less than 0.02), and prednisolone (p less than 0.05). For prednisolone there was a significant worsening of the prognosis (p less than 0.05) from the extremely sensitive patients through an intermediate group to the most resistant group. The prognostic significance of cellular drug resistance was independent of white-blood-cell count, age, sex, and hepatosplenomegaly. Leukaemic cells from boys were more resistant to thioguanine than those from girls. Thus, the short-term highly efficient MTT assay can help to predict long-term response to chemotherapy in childhood ALL.

Citing Articles

Secondary lesions and sensitivity to signaling inhibitors in iAMP21 acute lymphoblastic leukemia.

Hormann F, Ostergaard A, van den Broek S, Boeree A, van de Ven C, Escherich G Hemasphere. 2025; 9(1):e70069.

PMID: 39840380 PMC: 11746935. DOI: 10.1002/hem3.70069.


Genetic and Epigenetic Biomarkers Associated with Early Relapse in Pediatric Acute Lymphoblastic Leukemia: A Focused Bioinformatics Study on DNA-Repair Genes.

Albaqami W, Alshamrani A, Almubarak A, Alotaibi F, Alotaibi B, Alanazi A Biomedicines. 2024; 12(8).

PMID: 39200230 PMC: 11351110. DOI: 10.3390/biomedicines12081766.


Impact of Age on Pharmacogenomics and Treatment Outcomes of B-Cell Acute Lymphoblastic Leukemia.

Yoshimura S, Li Z, Gocho Y, Yang W, Crews K, Lee S J Clin Oncol. 2024; 42(29):3478-3490.

PMID: 39102629 PMC: 11458355. DOI: 10.1200/JCO.24.00500.


Investigation of inherited noncoding genetic variation impacting the pharmacogenomics of childhood acute lymphoblastic leukemia treatment.

Bhattarai K, Mobley R, Barnett K, Ferguson D, Hansen B, Diedrich J Nat Commun. 2024; 15(1):3681.

PMID: 38693155 PMC: 11063049. DOI: 10.1038/s41467-024-48124-4.


Utility of gene methylation evaluated with the HPLC method as a pharmacogenomic biomarker to predict asparaginase sensitivity in BCP-ALL.

Watanabe A, Miyake K, Yamada Y, Sunamura E, Yotani T, Kagami K Epigenetics. 2023; 18(1):2268814.

PMID: 37839090 PMC: 10578186. DOI: 10.1080/15592294.2023.2268814.